HK Stock Market Move | INNOVENT BIO (01801) rose more than 7% in the afternoon. Xinli bi-specific antibody cancer combination therapy filed for listing. New drug IBI3002 approved for clinical use.

INNOVENT BIO (01801) rose over 7% in the afternoon, up 5.82% to HK$42.7, with a turnover of HK$437 million. On the news front, INNOVENT BIO announced that the new drug application for the combination of Ipilimumab Injection and Pembrolizumab for neoadjuvant treatment of resectable microsatellite instability-high ("MSI-H") or mismatch repair deficient ("dMMR") colon cancer patients has been accepted by the National Medical Products Administration Drug Evaluation Center of China and included in the priority review process. In addition, on February 24, the National Medical Products Administration Drug Evaluation Center website announced that INNOVENT BIO's Class 1 new drug IBI3002 has been approved for clinical trials for the treatment of asthma. According to public information from INNOVENT BIO, IBI3002 is a dual-specific anti-IL-4R/TSLP antibody developed independently by the company, currently undergoing Phase 1 clinical studies in Australia. This is the first time the product has been approved for IND in China.